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Abstract
Background: The aim of this study was to evaluate the incidence and the risk factors of osteonecrosis of the jaw 
(ONJ) in a group of patients treated with zoledronic acid (ZA) for bone metastases from solid tumors and enrolled 
in a preventive dental program. 
Material and Methods: This 5-year retrospective longitudinal study included all consecutive oncological patients 
who underwent at least one infusion with ZA between 2004 and 2011 for bone metastases due to solid neo-
plasms. 
Results: Of the 156 patients enrolled in the study, 17 developed ONJ (10.89%). At the multivariate analysis, severe 
periodontal disease (P=0.025), tooth extraction (P<0.0001) and starting the preventive dental program after the 
beginning of ZA therapy (P=0.02) were the only factors which showed a significant association with the occur-
rence of ONJ.
Conclusions: This study demonstrated the importance of beginning dental prevention before zoledronic acid ex-
posure in reducing ONJ occurrence, especially in the long term. The results of this research show that control 
of periodontal disease and an increase in the time between tooth extraction and the first ZA administration are 
recommended in order to reduce the risk of ONJ development.
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Introduction
Bisphosphonate Related Osteonecrosis of the Jaw 
(BRONJ) is a well-known disease characterized by the 
presence in the maxillo-facial region of exposed bone 
for at least 8 weeks in a patient who underwent or who 
is receiving therapy with bisphosphonates (BP) and 
who did not undergo radiotherapy of the head and neck 
(1). This condition may be asymptomatic or can cause 
swelling of oral and perioral tissues with intense pain, 
bleeding, persistent purulent discharge and/or drain-
ing fistulas, severe halitosis sometimes associated with 
lower lip paresthesia, mobility and loosening of teeth, 
causing severe impairment in the quality of live.
The true incidence of BRONJ is still not known (2). A 
recent systematic review estimated an incidence in on-
cological patients ranging from 0 to 12,2 per 100,000 
patient-years (3).
Intravenous use (IV) of BP is the standard treatment for 
metastatic disease spread to the bone from solid tumors 
(i.e. breast, lung, prostate cancer), treatment of multiple 
myeloma and management of hypercalcemia caused by 
malignant diseases. IV BP treatment seems to deter-
mine a higher risk in the developing the diseases, while 
the oral use of the drugs longer than 3 years may also 
increase the risk of BRONJ. In addition, several other 
systemic and local factors, such as duration of BP ther-
apy, comorbidities, dento-alveolar surgical procedures, 
infectious dental diseases, concomitant use of drugs 
such as steroids and anti-angiogenic agents and poor 
oral hygiene have been reported to be associated with 
the development of BRONJ (1,4). 
A staging system of the condition has been firstly pub-
lished in 2007 and subsequently modified to obtain a 
more accurate stratification of patients with BRONJ and 
specific treatment strategies for each stage (5). At the 
moment four stages of BRONJ have been identified [0-3] 
in addition to a “at risk category” indicating asymptom-
atic patients without clinical evidence of necrotic bone 
who have been treated with IV or oral BP.
The exact underlying etiopathogenic mechanism of 
BRONJ is still unclear, therefore preventive measures 
are restricted to controlling the known risk factors. 
Several clinical recommendations for operators in the 
fields of oral health have been proposed, but their real 
effectiveness in reducing the incidence of BRONJ is un-
known because they are mainly based on expert opinion 
and case series (6). 
In the present retrospective study we investigate the 
5-years incidence and possible risk factors of BRONJ in 
a group of patients affected by solid tumor and treated 
with zoledronic acid (ZA). 
Materials and Methods
The present study was approved by the Ethic Commit-
tee of the Azienda Ospedaliero-Universitaria of Parma, 
Italy. In this retrospective analysis we included all the 
patients scheduled to receive ZA therapy or already in 
ZA therapy (4 mg in 250 ml saline solution and infused 
over 45 min every 28 days) at the Oncological Unit of 
the Azienda Ospedaliero-Universitaria di Parma for 
bone metastases due to solid neoplasms and referred 
to Dentistry Unit, Oral Medicine, Pathology and Laser 
Assisted Surgery from 01-01-2004 to 01-01-2011 in or-
der to evaluate oral health status and the presence of any 
possible infection or inflammation which could require 
dental intervention. 
Of the 369 patients initially included, 213 were then 
excluded from the study because, although they were 
treated with the ZA, they refused to accept dental care 
in our unit and were lost to subsequent observations.
For each of the remaining 156 patients demographic 
data, tumor type, number of ZA administrations, pres-
ence of bone metastases, diagnosis of diabetes, medi-
cations (corticosteroids, anticoagulants, anticancer 
therapies) and smoking habits were recorded. We also 
recorded if the dental care program started before or af-
ter the first ZA infusion. 
All these patients underwent clinical inspection and an 
orthopantomography (OPT) examination. In particu-
lar patients were checked for periodontal status (tooth 
mobility, periodontal diseases with particular regard to 
severe periodontal disease, recorded as loss of clinical 
attachment >50%, tooth mobility grade II or III, plaque 
index >50%, bleeding on probing >50%, furcation de-
fects), presence of prosthetic rehabilitation (fixed or 
removable), presence of root fragments, decay, apical 
periodontitis and edentulism. All the patients were ad-
vised to undergo a dental check every 4 months and a 
professional oral hygiene recall every 6 to 12 months 
which included personalized instructions for daily home 
oral hygiene procedures. Those patients who, during the 
ZA treatment period, had to undergo tooth extractions 
followed a specific protocol (Vescovi et al., 2013).
The patients examined before the beginning ZA therapy 
received specific dental care designed to prevent occur-
rence of BRONJ. This included extraction of the teeth 
considered lost to periodontal or carious lesions, treat-
ment of periodontal diseases and 6 to 12-month profes-
sional oral hygiene recalls. Patients were not given ZA 
until 1 month after an extraction. The conservative, 
endodontic or prosthetic treatments were planned and 
carried out also in the course of ZA treatment. 
The BRONJ staging system approved in 2007 by the 
AAOMS and subsequently updated in 2009 (1) was 
used to classified the patients affected by the disease. 
- Statistical analysis
We calculated the 5-years incidence of BRONJ in pa-
tients who received ZA therapy accordingly with the 
time they had received dental treatment. The evaluation 
of the incidence of BRONJ required all patients to be 
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followed for a similar period of time. Consequently, to 
assess the incidence of BRONJ the period considered 
started with the date of the first ZA administration and 
ended with the occurrence of BRONJ or the last clinical 
examination. For this reason the observation time was 
standardized for all the patients at 60 months (5 years) 
from the beginning of ZA treatment. 
To assess the possible risk factors of BRONJ we com-
pared the patients affected by BRONJ (BRONJ group) 
with the patients who did not develop the disease (no-
BRONJ group). A multivariate binary model of logistic 
regression was used including the variables that showed 
a P<0.06 at a first univariate analysis.
The Kaplan Meier test followed by the Log-Rank tests 
was used to evaluate the difference in time between 
the onset of BRONJ in patients who started the preven-
tive dental program after the beginning of ZA therapy 
(group 1) compared to the ones who stared the preven-
tive dental program before the beginning of ZA therapy 
(group 2).
We evaluated occurrence of BRONJ at 5 years from the 
first ZA administration in the patients who did not under-
go tooth extraction, patients who underwent tooth extrac-
tion before ZA therapy and patients who underwent tooth 
extraction after ZA therapy with Kaplan-Meier analysis 
and we used Log-Rank tests to assess significance.
Chi-square test was used to compare survival between 
in BRONJ and no-BRONJ groups. 
All the data recorded were analyzed using SPSS (v 21.0, 
IBM, USA). 
Significant level was set at P<0.05.
Results
Out of all the patients enrolled, 17/156 (10.89%) de-
veloped BRONJ (group BRONJ: 14 women, 82.4%, 3 
men, 17.6%) whereas 139 did not (group no-BRONJ: 
104 women, 74.8%, 35 men, 25.2%). Figure 1 shows the 
Kaplan-Meier estimates of the probability to be free from 
ONJ. Univariate analysis of possible risk factors between 
BRONJ group and no-BRONJ is summarized in table 1: 
receiving specific dental prevention after the beginning 
of ZA therapy (group 1), the presence of severe periodon-
tal disease and tooth extractions were the only variables 
significantly associated with BRONJ and these factors re-
mained significant after the multivariate analysis (table 2). 
Figure 2 shows a Kaplan Meier curve from which it is 
clear that patients who started the preventive dental pro-
gram before the beginning of ZA therapy (group 2) tend 
not to develop BRONJ in the long term in comparison 
to group 1 patients, who started the preventive dental 
program after the beginning of ZA therapy. In particu-
lar, the final incidence between the two curves is more 
evident 2 years after the beginning of the ZA therapy.
Figure 3 shows a Kaplan Meier curve of the variable 
“tooth extractions” compared to patients who had 
never undergone extractions (n = 106), those who had 
extractions before ZA therapy (n = 30) and those who 
had extractions carried out after the beginning of the 
ZA therapy (n = 20).  From this curve it is clear that 
tooth extractions have an important role in the onset of 
BRONJ and how the difference is more evident 2 years 
after the first ZA administration. In particular, compar-
ing patients who had never undergone extractions to 
those who had extractions before ZA therapy, a statis-
tically significant difference was observed (P=0.003). 
This difference becomes more evident (P<0.001) com-
paring patients who had never undergone tooth extrac-
tions to those who had extractions after ZA therapy. No 
statistical significant difference was obtained compar-
ing patients who underwent tooth extractions before 
Fig. 1. Time of ONJ occurrence since the beginning of ZA therapy.
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ZA therapy to those who had the extractions after ZA 
therapy (dotted black line vs grey line, P=0.5).
The mandible was the site most affected by BRONJ 
(9/17, 52.9%), whereas the maxilla was involved in 6/17 
cases (35.3%). In two patients (11.8%) BRONJ was pre-
sent in both jaws. Seven cases were classified as stage I, 
while 10 as stage II.
The 17 patients who developed BRONJ were treated in 
our Unit with different protocols:
- 6 patients underwent laser therapy (LT) applications 
only;
- 4 patients were treated with antibiotics only;
- 3 patients underwent conventional oral surgery and 1 
of these received LT applications;
- 4 patients underwent laser-assisted surgery and LT ap-
plications.
Complete healing at 6 months (complete healing of the 
wounds without any symptoms or sign of infection) was 
obtained for 13/17 patients (76.5%). In particular out of 
the 13 patients healed, 4 were treated with laser-assist-
ed surgery and LT, 3 with conventional oral surgery, 4 
underwent LT only and 2 were treated with antibiotic 
therapy. 
At 5 years 12/17 (70.6%) and 99/139 (71.2%) patients 
had died in the BRONJ group and in the no-BRONJ 
group, respectively. At Chi-squared test no statistically 
significant difference was recorded.
Discussion
ZA is a potent nitrogen-containing bisposphonate fre-
quently used for the treatment of lytic lesions in patients 
affected by multiple myeloma and for the management 
of skeletal-related events associated with bone metas-
BRONJ
Group
(n=17)
No-BRONJ
Group
(n=139)
P*
Age, mean  ± SD 69.0 ± 11.2 64.6 ± 15.1 0.23
Gender, n (%)
Female
Male
14 (82.0)
3 (18.0)
104 (75.0)
35 (25.0) 0.50
Dental Prevention
Group 1, n (%)
Group 2, n (%)
11 (64.7)
6 (35.3)
49 (35.3)
90 (64.7) 0.02
Smokers, n (%) 5 (29.4) 25 (17.9) 0.30
Primary  malignancy site, n (%)
Breast
Prostate
Others
12 (70.6)
2 (11.8)
3 (17.6)
99 (71.2)
15 (10.8)
16 (11.5)
0.81
Medications
N of ZA administration, mean  ± SD
Corticosteroids, n (%)
Anticoagulants, n (%)
Antiangiogenic agents, n (%)
Alchilants, n (%)
CMF therapy, n (%)
Taxane, n (%) 
22.3 ± 23.7
8 (47.1)
1 (5.9)
6 (35.3)
5 (29.4)
10 (58.8)
23.4 ± 17.8
54 (38.8)
11 (7.9)
47 ( (33.8)
39 (28.1)
40 (28.8)
0.97
0.48
0.77
0.86
0.86
0.06
Dental variables
Removable prosthesis, n (%)
Dental implants, n (%)
Severe periodontal disease, n (%)
Tooth extraction, n (%)
4 (23.5)
1 (5.9)
6 (35.3)
13 (76.5)
59 (42.4)
8 (5.8)
23 (16.5)
37 (26.6)
0.31
0.98
0.025
<0.001
Table 1. Univariate analysis of BRONJ risk factors.
* P BRONJ group versus No-BRONJ group; SD= Standard Deviation; CMF = cyclophosph-
amide, methotrexate, fluorouracil; ZA = zoledronic acid
Odd Ratio         CI     P
Preventive dental
program after ZA 6.96 1.79 - 26.98 0.005
Taxane use 2.18 0.68 – 6.98 0.189
Severe periodontal 
disease 4.56 1.21 – 17.20 0.025
Tooth extractions 13.9 3.55 – 54.38 <0.001
CI = Confidence Intervals of the Odd Ratio; ZA = zoledronic acid
Table 2. Results of the multivariate logistic regression.
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tases. In 2007, the U.S. Food and Drug Administration 
(FDA) also approved the use of an annual infusion of 
zoledronate for the treatment of postmenopausal osteo-
porosis (4). 
ZA down-regulates osteoclast activities leading to the 
reduction of bone turnover and inhibition of bone re-
sorption. An uncommon but potential severe side ef-
fect of this drug is osteonecrosis of the jaw, firstly re-
ported by Marx et al. in 2003 (7). There is considerable 
variability in the reported incidence and prevalence of 
BRONJ occurrence in oncological patients. The reasons 
of the dishomogeneity in the reported data are several 
and include use of other drugs that may also impact 
bone health, such as glucocorticoids or antiangiogenic 
drugs. Moreover the incidence of ONJ in the oncology 
patient population may be affected by the type of malig-
nancy being treated. In our study the 5-years incidence 
was 10.89% and our data confirmed the results of a re-
cent systematic review that estimated an incidence in 
oncological patients ranging from 0 to 12,2 per 100,000 
patient-years (3).
The increasing number of new cases of osteonecrosis 
associated to ZA and other anti-resorbtive agents lead 
the scientific community to promote preventive mea-
sures in order to reduce the incidence of BRONJ. The 
effectiveness of preventive strategies is strictly related 
to the knowledge of the most important risk factors. In 
our study tooth extraction (P<0,0001) and severe peri-
odontal disease (P=0,025) were the only dental vari-
ables which showed a significant association with the 
occurrence of BRONJ. Although a minor percentage 
of BRONJ is related to non-surgical causes, literature 
clearly demonstrates that BRONJ is preceded by dento-
alveolar surgical interventions in the majority of cases 
(1,4,5). In a multi-center retrospective 4-year study, 
Vescovi et al. found that in 567 cases of BRONJ, 63.8% 
were associated with a prior dento-alveolar procedure 
(8). It was calculated that tooth extraction was associ-
ated with a 16-fold increased risk for ONJ in cancer pa-
tients exposed to zoledronate (9). The role of impaired 
post extractive healing has been investigated in some 
studies where tooth extractions were performed in rats 
treated with BPs (10,11). Analyzing the alveolar socket 
of BP-treated rats, the authors found delayed bone turn-
over, absence of bone resorption, poor vascularity with 
a low number of osteoclasts and concluded that these 
findings could be associated with the onset BRONJ. 
To better investigate the impact of oral surgery on 
BRONJ a specific analysis of the timing relating to tooth 
extractions in relation to BP treatment was performed 
(Fig. 2). As already reported in literature (1,4,5) the re-
sults of this analysis also showed that tooth extractions 
have a significant impact on the development of BRONJ 
and that this event is particularly evident 2 years from 
the beginning of BP treatment. 
This study confirms that the incidence of BRONJ in 
patients who underwent tooth extractions after the ZA 
therapy is higher in comparison to patients who did 
not have extractions (P<0.001). Moreover, from this 
analysis, also the patients who had extractions before 
the beginning of ZA treatment developed BRONJ more 
frequently (P=0.003) with respect to the patients never 
subjected tooth extraction.
This last finding may reflect the time needed for the 
bone to recover following the extraction or dental al-
veolar intervention and the beginning of BP therapy. 
Although healing events in the tooth extraction sock-
et have been studied extensively in rats, there are few 
Fig. 2. Time of begin of the dental prevention programme and 
BRONJ.
Evaluation of the occurrence of BRONJ at 5 years from the first ZA 
administration in the group 1 (continuous black line) and group 2 
(dotted black line).
Fig. 3. Tooth extractions and BRONJ onset
Evaluation of the occurrence of BRONJ at 5 years from the first ZA 
administration in the patients who did not undergo to tooth extrac-
tion (continuous black line), patients who underwent tooth extraction 
before ZA therapy (dotted black line) and patients who underwent 
tooth extraction after ZA therapy (gray line).
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studies that have investigated these processes in hu-
mans. Amler and colleagues found that after extraction 
a blood clot filled the socket (12). After 7 days, the clot 
was replaced with granulation tissue and then by col-
lagen after 20 days. In this phase bone began forming at 
the base and the periphery of the extraction socket. At 5 
weeks two-thirds of the extraction socket had filled with 
immature, woven bone. Osteogenic tissue proliferates 
and trabecular bone is formed followed by a process 
of bone maturation at 8 weeks from tooth extraction. 
According to some authors BP could impair this phase 
of bone maturation, in which osteoclasts are involved, 
leading to osteonecrosis (13).
In literature there are no data available about the exact 
time needed from bone to recover from dental extrac-
tion and/or surgical procedure in oncological patients. 
It is clear that individual as well as iatrogenic factors 
may influence this ability. Usually, based on the experi-
ence with patients affected by osteoradionecrosis, sev-
eral authors suggest that the beginning of BP therapy 
(or of antioangiogenic treatment) should be delayed un-
til “the extraction site has mucosalized (14-21 days) or 
until there is adequate osseous healing” (not specified) 
(4). In our experience and from the analysis of the data 
obtained in the present study, if the waiting time does 
not represent a relevant concern for the oncologic prog-
ress, we propose that a period longer than 1 month (e.g. 
2 months) from the extraction to the first administration 
of the drug is recommended in order to reduce the risk 
of BRONJ development.
From our analysis severe periodontal disease was sig-
nificantly associated with BRONJ onset and this find-
ing is consistent with the literature. A retrospective case 
control study by Kos showed that the percentage of pa-
tients with deep teeth pockets was significantly higher 
among BRONJ cases (14).
The role of periodontal disease as co-factor in the etio-
pathogenesis of BRONJ has also been confirmed by 
two studies on animal models where periodontitis was 
experimentally induced in rats treated with BP (15-17). 
The authors found ONJ-like lesions only in rat with 
induced periodontal disease. According these models, 
periodontal disease creates periodontal tissue inflam-
mation, which, in normal condition, induces alveolar 
bone resorption. In presence of bisphosphonates the 
osteoclasty activity is greatly diminished resulting in 
retarded resorption of bone that then become exposed to 
an environment rich in bacterial toxins, inflammatory 
cytokines and oxidative stress. Such environment is 
highly toxic to bone cells and results in osteonecrosis.
Therefore, a goal of the preventive management of pa-
tient under or scheduled for BP therapy should be the 
control of periodontal disease, mainly through non-sur-
gical periodontal treatment together with oral hygiene 
advices.
Regarding the effectiveness of the dental preventive 
program, we observed a significant reduction in the 
incidence of BRONJ in patients who received specific 
dental prevention prior to ZA treatment in comparison 
to those who were evaluated during ZA treatment (6.3% 
vs 18.3%). 
This data confirms and reinforces the results from other 
studies in literature, where it has been reported that 
dental prevention in patients scheduled to start may re-
duce, but not eliminate, the risk of developing BRONJ 
in patients treated with ZA (18,19). 
As can be noted, in the first 2 years of ZA treatment the 
incidence of the disease in the two groups is similar. 
However, this long longitudinal analysis shows that the 
risk of BRONJ can be reduced up to 3-fold in the long 
term (after 2 years from the first ZA administration) 
through a dental prevention program. It could be that 
other co-factors, both systemic and local, may interfere 
with the onset of the pathology in the first 2 years of 
ZA treatment (i.e. genetic factors, underlying diseases, 
drug therapies). 
According to these results, relative to two groups of on-
cological patients from the same Oncological Unit eva-
luated during the same timeframe, and in line with the 
findings of other studies (18,19), dental prevention re-
mains the most significant approach to manage patients’ 
oral health before and during treatment with BP.
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